netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Please also refer to the Cancer Drugs Fund list

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
 note  Use in accordance with local guidelines
Arsenic trioxide injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
Atezolizumab injection (lung cancer indications)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
   
Atezolizumab injection (urothelial cancer indications)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Avelumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Approved for use as per NICE technology appraisal guidance (see links below):

 

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Axitinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bosutinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Brentuximab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Approved as per NICE Technology Appraisal guidance

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
Carfilzomib injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
   
Ceritinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use as per NICE Technology Appraisal guidance (see links below):

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
   
Eribulin injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Ibrutinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Approved for use as per NICE technology appraisal guidance below

 
Link  MHRA Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib tabs
View adult BNF View SPC online
Formulary
Red
 
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Ketoconazole tabs
View adult BNF View SPC online
Restricted Drug Restricted
Red

Approved off-label indication:

Management of castration refractory prostate cancer

Dose = 200-400mg three times daily

 
   
Midostaurin caps
View adult BNF View SPC online
Formulary
Red

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Niraparib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Nivolumab injection (GSTFT and KCH)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Approved for use as per NICE technology appraisal guidance below

 
Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
   
Nivolumab injection (lung, head and neck cancers - GSTFT only)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
   
Nivolumab injection (urothelial cancer - GSTFT only)
View adult BNF View SPC online
Formulary
Red

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
   
Olaparib caps, tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Due to differences in dosing and bioavailability, capsules and tablets should not be substituted on a milligram-to-milligram basis. To avoid medication errors, prescribers should specify formulation and dose on each prescription.

 
Link  NICE TA381: Olaparib for relapsed, platinum-sensitive, BRCA positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
   
Olaratumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
Approved for treating advanced soft tissue sarcoma as per NICE TA465 
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Palbociclib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use as per NICE technology appraisal guidance below 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Panitumumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved as per restrictions in the NICE guidance

 
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Panobinostat caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pegaspargase injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
   
Pembrolizumab injection (lung cancer indications)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

For non-small-cell lung cancer as per NICE Technology appraisals below

 
Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
   
Pembrolizumab injection (skin cancer indications)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
For skin cancer indications as per NICE technology appraisals below 
Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
   
Pembrolizumab injection (urothelial cancer indications)
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

For urothelial cancer indications as per NICE Technology appraisals below

 
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
   
Pertuzumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use as per NICE technology appraisal guidance below 

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Ponatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for CML and ALL as per NICE TA451

 
Link  MHRA Apr 2017: Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Regorafenib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use as per NICE technology appraisal guidance below 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Ribociclib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved for use as per NICE technology appraisal guidance below

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Ruxolitinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Trametinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
Streptozocin injection
View adult BNF View SPC online
Unlicensed Drug Unlicensed
Red

Locally advanced and metastatic neuroendocrine tumours (predominantly pancreas but also small/large bowel and lung)

For named supervising consultants only in accordance with the prescribing protocol and proforma

 
   
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine injection
View adult BNF View SPC online
Formulary
Red
 
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved off-label indication:

Treatment of neurofibromatosis type 2

For consultant specialists in accordance with a nationally commissioned service protocol

 
   
Bevacizumab injection
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

Approved as per indications in the Cancer Drugs Fund

 
   
08.01.05  Expand sub section  Bexarotene
Bexarotene caps
View adult BNF View SPC online
Formulary
Red
Use in accordance with LCNDG guidance 
   
08.01.05  Expand sub section  Bortezomib to top
Cytotoxic Drug Bortezomib injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For relapsed multiple myeloma as per criteria in the Cancer Drugs Fund

 
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab injection (colorectal cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use as per NICE technology appraisal guidance (see links below)

 
Link  MHRA Feb 2014: Cetuximab: Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cetuximab injection (head and neck cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use as per NICE technology appraisal guidance (see links below)

 
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.05  Expand sub section  Crisantaspase
Crisantaspase injection
View adult BNF View SPC online
Formulary
Red
 
   
Asparaginase injection
View adult BNF View SPC online
Unlicensed Drug Unlicensed
Red
Acute lymphoid leukaemia 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Temozolomide caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
Cytotoxic Drug Temozolomide caps
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine

Approved off-label indication:

Treatment of pituitary adenomas refractory to surgery and radiotherapy

Initiation restricted to Consultant Endocrinologists who are part of the Trust MDM, in accordance with a treatment protocol at KCH

 
   
08.01.05  Expand sub section  Erlotinib
Erlotinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide to top
Cytotoxic Drug Hydroxycarbamide caps, tabs
View adult BNF View SPC online
Formulary

Red Traffic Light Cancer indications

Amber Traffic Light Non-cancer licensed indications

 
   
08.01.05  Expand sub section  Imatinab
Imatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
08.01.05  Expand sub section  Ipilimumab
Ipilimumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
   
08.01.05  Expand sub section  Mitotane
Mitotane tabs
View adult BNF View SPC online
Restricted Drug Restricted
Red

Treatment of patients with:

  • Biochemical or radiological evidence of persistent or relapsed adrenocortical carcinoma
  • Apparent complete resection of adrenocortical carcinoma for adjuvant therapy
 
   
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin injection
View adult BNF View SPC online
Formulary
Red
 
   
08.01.05  Expand sub section  Platinum compounds to top
Cytotoxic Drug Carboplatin injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG121: Lung cancer: diagnosis and management
   
Cytotoxic Drug Cisplatin injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG121: Lung cancer: diagnosis and management
   
Cytotoxic Drug Oxaliplatin injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG131: Colorectal cancer: diagnosis and management
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
   
08.01.05  Expand sub section  Procarbazine
Cytotoxic Drug Procarbazine caps
View adult BNF View SPC online
Formulary
Red
 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cabozantinib caps (Cometriq)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE Technology Appraisal guidance (see links below): 

 

 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Cabozantinib tablets (Cabometyx)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved as per NICE Technology Appraisal guidance (see links below): 

 

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
   
Crizotinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use as per NICE technology appraisal guidance (see links below):


 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dasatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus tabs (breast cancer and renal cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved as per NICE TA guidance (see links below)

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Everolimus tabs (neuroendocrine tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use in neuroendocrine tumours as per NICE TA449

 
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
   
Lenvatinib caps (renal cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE TA guidance (see links below)

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Nilotinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Nintedanib caps (Vargatef® Non-small-cell lung cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved for use in NSCLC as per NICE TA347

 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Osimertinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Pazopanib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Sorafenib tablets
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved as per NICE Technology Appraisal guidance

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
   
Sunitinib caps (neuroendocrine tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved for use in neuroendocrine tumours as per NICE TA449

 
Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Sunitinib caps (renal cell, and gastrointestinal stromal tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use in renal cell and gastrointestinal stromal tumours as per NICE TA169 and NICE TA179 
Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
   
Tivozanib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE TA guidance (see links below)

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Vemurafenib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG121: Lung cancer: diagnosis and management
Link  NICE CG81: Advanced breast cancer: diagnosis and treatment
Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Link  NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
   
Cytotoxic Drug Paclitaxel albumin injection (Abraxane)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

Approved as per NICE Technology Appraisal guidance

 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
Cytotoxic Drug Paclitaxel injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG121: Lung cancer: diagnosis and management
Link  NICE CG81: Advanced breast cancer: diagnosis and treatment
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE CG131: Colorectal cancer: diagnosis and management
   
Cytotoxic Drug Topotecan injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
   
08.01.05  Expand sub section  Trabectedin to top
Cytotoxic Drug Trabectedin injection
View adult BNF View SPC online
Formulary
Red
 
Link  NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
   
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Trastuzumab emtansine injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

 
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
Cytotoxic Drug Trastuzumab injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
   
08.01.05  Expand sub section  Tretinoin
Tretinoin caps
View adult BNF View SPC online
Formulary
Red
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

Green

Specialist and non-specialist initiation  

Grey

Not recommended for prescribing  

netFormulary